Current drug metabolism
- Label
- Current drug metabolism (literal)
- Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#rivistaDi
- HIV-1 reverse transcriptase inhibitors: current issues and future perspectives. (Articolo in rivista) (http://www.cnr.it/ontology/cnr/individuo/prodotto/TIPO1101)
- Multifunctional anti-cancer nano-platforms are moving to clinical trials (Articolo in rivista) (Prodotto della ricerca)
- Prodrugs of Quercetin and Resveratrol: A Strategy Under Development (Articolo in rivista) (Prodotto della ricerca)
- Xenobiotic Metabolizing Cytochrome P450 in Pig, a Promising Animal Model (Articolo in rivista) (Prodotto della ricerca)
- Combinations against combinations: associations of anti-HIV 1 revese transcriptase drugs challenged by constellations of drug resistance mutations. (Articolo in rivista) (http://www.cnr.it/ontology/cnr/individuo/prodotto/TIPO1101)
- Electroporation in DNA vaccination protocols against cancer. (Articolo in rivista) (Prodotto della ricerca)
- Alternative label
- Current drug metabolism. (literal)
- Language
- eng (literal)
- Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#issn
- 1389-2002 (literal)
- Preferred label
- Current drug metabolism (literal)
- Publisher
- Bentham Science Publishers Hilversum : NLD (literal)
Incoming links:
- Rivista
- Combinations against combinations: associations of anti-HIV 1 revese transcriptase drugs challenged by constellations of drug resistance mutations. (Articolo in rivista) (http://www.cnr.it/ontology/cnr/individuo/prodotto/TIPO1101)
- HIV-1 reverse transcriptase inhibitors: current issues and future perspectives. (Articolo in rivista) (http://www.cnr.it/ontology/cnr/individuo/prodotto/TIPO1101)
- Electroporation in DNA vaccination protocols against cancer. (Articolo in rivista) (Prodotto della ricerca)
- Xenobiotic Metabolizing Cytochrome P450 in Pig, a Promising Animal Model (Articolo in rivista) (Prodotto della ricerca)
- Prodrugs of Quercetin and Resveratrol: A Strategy Under Development (Articolo in rivista) (Prodotto della ricerca)
- Multifunctional anti-cancer nano-platforms are moving to clinical trials (Articolo in rivista) (Prodotto della ricerca)
